Przejdź do treści

Filtry

Dane naukowe

Podręcznik/instrukcje

Aktualności

Uterine muscle relaxant drugs for threatened miscarriage

Not enough evidence to say if drugs that relax the muscles of the uterus can prevent threatened miscarriage.

Miscarriage is the loss of a baby in the very early weeks of pregnancy (before 20 weeks), before the baby would be able to survive on its own. This can be a devastating loss to expectant parents. Threatened miscarriage is when there is vaginal bleeding, and sometimes pain, but when the cervix remains closed. The review of studies found just one small trial on uterine relaxant drugs to prevent miscarriage, but the study provided insufficient data to be able to assess its effect adequately. More research is needed.

Wprowadzenie

Miscarriage is the spontaneous loss of a pregnancy before the fetus is viable. Uterine muscle relaxant drugs have been used for women at risk of miscarriage in the belief they relax uterine muscle, and hence reduce the risk of miscarriage.

Cele

To assess the effects for the woman and her baby of uterine muscle relaxant drugs when used for threatened miscarriage.

Metody wyszukiwania badań

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (10 September 2009).

Kryteria doboru badań

Randomised trials were included, and quasi-randomised trials were excluded. The participants were women with a pregnancy of less than 20 weeks' gestation having a threatened miscarriage. The interventions were any uterine muscle relaxing drugs (including tocolytic and antispasmodic agents) compared with either placebo or no drug. Primary outcomes for the review were miscarriage: defined as spontaneous pregnancy loss before fetal viability, baby death (stillbirth or neonatal death) and maternal death.

Zbieranie i analiza danych

Both review authors independently assessed studies for eligibility and trial quality, and extracted data.

Główne wyniki

One poor quality trial (170 women) was included. This compared a beta-agonist with placebo. There was a lower risk of intrauterine death associated with the use of a beta-agonist (relative risk (RR) 0.25, 95% confidence interval (CI) 0.12 to 0.51). Preterm birth was the only other outcome reported (RR 1.67, 95% CI 0.63 to 4.38).

Wnioski autorów

There is insufficient evidence to support the use of uterine muscle relaxant drugs for women with threatened miscarriage. Any such use should be restricted to the context of randomised trials.

Cytowanie
Lede RL, Duley L. Uterine muscle relaxant drugs for threatened miscarriage. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD002857. DOI: 10.1002/14651858.CD002857.pub2.

Używamy plików cookie

Używamy niezbędnych plików cookie, aby nasza strona mogła działać. Chcielibyśmy również ustawić opcjonalne pliki cookie do analizy, aby pomóc nam udoskonalić tę stronę. Nie będziemy ustawiać opcjonalnych plików cookie, chyba że je włączysz. Użycie tego narzędzia spowoduje ustawienie pliku cookie na Twoim urządzeniu, aby zapamiętać Twoje preferencje. W każdej chwili możesz zmienić swoje preferencje dotyczące plików cookie, klikając na link "Ustawienia plików cookie" znajdujący się w stopce każdej strony.
Bardziej szczegółowe informacje na temat używanych przez nas plików cookie można znaleźć na naszej stronieStrona plików cookies

Zaakceptuj wszystkie
Skonfiguruj